×
About 6,265 results

ALLMedicine™ Candidiasis Center

Research & Reviews  1,830 results

Mixed Vaginitis Due to Bacterial Vaginosis and Candidiasis.
https://doi.org/10.1097/LGT.0000000000000641
Journal of Lower Genital Tract Disease; Benyas D, Sobel JD

Nov 30th, 2021 - The aim of the study was to review recent clinic cases with mixed vaginitis due to bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) with reference to demographics, clinical presentation, diagnosis, and treatment. This is a retrospective...

Humoral immune responses against facultative pathogen Candida utilis in atopic patients...
https://doi.org/10.1016/j.imbio.2021.152154
Immunobiology Paulovičová E, Hrubiško M

Nov 27th, 2021 - Vulvovaginal candidiasis is one of the most commonly reported female genital tract infections, affecting approximately 70-75% of childbearing age women at least once during their lifetime. Approximately 50% of patients have refractory episodes and...

Candida PCR Diagnosis Strategy in Patients From Intensive Care Units
https://clinicaltrials.gov/ct2/show/NCT04874441

Nov 24th, 2021 - Invasive candidiasis is a serious infection caused by yeasts of the genus Candida sp. Their incidence is increasing, particularly in intensive care. The prognosis is severe and depends on the early initiation of adequate antifungal treatment. At p...

Inflammasome-mediated GSDMD activation facilitates escape of Candida albicans from macr...
https://doi.org/10.1038/s41467-021-27034-9
Nature Communications; Ding X, Kambara H et. al.

Nov 20th, 2021 - Candida albicans is the most common cause of fungal sepsis. Inhibition of inflammasome activity confers resistance to polymicrobial and LPS-induced sepsis; however, inflammasome signaling appears to protect against C. albicans infection, so inflam...

see more →

Guidelines  8 results

British HIV Association/British Infection Association guidelines on the management of o...
https://doi.org/10.1111/hiv.12806
HIV Medicine 7 References; Dockrell DH, O’Shea D et. al.

Nov 2nd, 2019 - British HIV Association/British Infection Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019.|2019|Dockrell DH,O’Shea D,Cartledge JD,Freedman AR,|diagnosis,dru...

Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727169
American Journal of Respiratory and Critical Care Medicine; Hage CA, Carmona EM et. al.

Aug 31st, 2019 - Background: Fungal infections are of increasing incidence and importance in immunocompromised and immunocompetent patients. Timely diagnosis relies on appropriate use of laboratory testing in susceptible patients.Methods: The relevant literature r...

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormyc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394968
Haematologica Tissot F, Agrawal S et. al.

Dec 25th, 2016 - The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematologic malignancies or he...

Managing xerostomia and salivary gland hypofunction: executive summary of a report from...
https://doi.org/10.14219/jada.2014.44
Journal of the American Dental Association (1939); Plemons JM, Al-Hashimi I et. al.

Aug 2nd, 2014 - Xerostomia, also known as "dry mouth," is a common but frequently overlooked condition that is typically associated with salivary gland hypofunction, which is the objective measurement of reduced salivary flow. Patients with dry mouth exhibit symp...

Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis.
https://doi.org/10.1007/s00134-013-3134-2
Intensive Care Medicine; Montravers P, Dupont H et. al.

Oct 25th, 2013 - Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis.|2013|Montravers P,Dupont H,Eggimann P,|therapeutic use,drug effects,drug therapy,microbiology,drug therapy,microbiology,

see more →

Drugs  387 results see all →

Clinicaltrials.gov  93 results

Candida PCR Diagnosis Strategy in Patients From Intensive Care Units
https://clinicaltrials.gov/ct2/show/NCT04874441

Nov 24th, 2021 - Invasive candidiasis is a serious infection caused by yeasts of the genus Candida sp. Their incidence is increasing, particularly in intensive care. The prognosis is severe and depends on the early initiation of adequate antifungal treatment. At p...

A Pilot Study to Evaluate the Efficacy and Safety of Lactobacillus Species Suppositories on Vaginal Health and pH
https://clinicaltrials.gov/ct2/show/NCT05060029

Nov 10th, 2021 - The vaginal microbiome is said to be the first line of defence against vaginal infection, due to competitive exclusion and the destruction of pathogenic microbes. The vagina remains relatively sterile until a woman reaches puberty, after which the...

A Study to Assess the Effect of Concomitant Administration of Fluconazole on the Clinical Pharmacokinetics of Methadone
https://clinicaltrials.gov/ct2/show/NCT00000788

Nov 3rd, 2021 - Injection drug users constitute the second largest subset of the U.S. population at risk for HIV infection and AIDS-associated mortality. Narcotic addiction is often treated by use of methadone. Fluconazole has been shown to be highly effective in...

A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations
https://clinicaltrials.gov/ct2/show/NCT01039584

Oct 13th, 2021 - This was a study that compared the efficacy and safety of a generic butoconazole nitrate vaginal cream, 2% to Gynazole-1 (butoconazole nitrate) Vaginal Cream, 2% in the treatment of vulvovaginal candidiasis caused by Candida species.

A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis
https://clinicaltrials.gov/ct2/show/NCT05074602

Oct 12th, 2021 - The purpose of this study is to evaluate the Efficacy and Safety of SHR8008 capsule In Subjects With Recurrent Vulvovaginal Candidiasis

see more →

News  185 results

Inhaled Steroid Disappoints for COVID-19
https://www.medpagetoday.com/infectiousdisease/covid19/95808

Nov 22nd, 2021 - COVID-19 outpatients treated with the inhaled corticosteroid ciclesonide (Alvesco) obtained no symptom relief beyond that seen in a placebo group, a large randomized trial showed. Odds of needing hospitalization or an emergency department (ED) vis...

Miltefosine Granted Orphan Drug Approval for Invasive Candidiasis
https://www.medscape.com/viewarticle/962804

Nov 12th, 2021 - The US Food and Drug Administration (FDA) has granted orphan drug designation approval of miltefosine (Profounda, Inc) for the treatment of invasive candidiasis. This condition includes the potentially life-threatening candidemia, which is among t...

EC-18 Reduces Duration and Incidence of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
https://www.onclive.com/view/ec-18-reduces-duration-and-incidence-of-chemoradiation-induced-oral-mucositis-in-head-and-neck-cancer

Oct 21st, 2021 - Treatment with the small molecule oral immunomodulator EC-18 resulted in a reduction in both the duration and incidence of severe oral mucositis (SOM) in patients with head and neck cancer who are undergoing concurrent chemoradiation, meeting both...

Oteseconazole Promising for Recurrent Yeast Infections
https://www.medscape.com/viewarticle/960068

Sep 30th, 2021 - A phase 3 randomized, double-blind, controlled trial has shown that oteseconazole (Mycovia Pharmaceuticals), an oral antifungal agent, is safe and effective in treating acute and recurrent yeast infections (vulvovaginal candidiasis [VVC]) and in p...

U2 Plus Pembrolizumab Shows Continued Efficacy at 5 Years in CLL and Richter’s Transformation
https://www.onclive.com/view/u2-plus-pembrolizumab-shows-continued-efficacy-at-5-years-in-cll-and-richter-s-transformation

Sep 20th, 2021 - The triplet combination of umbralisib (Ukoniq), ublituximab (U2), and pembrolizumab (Keytruda) demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter’s tra...

see more →

Patient Education  3 results see all →